國家衛生研究院 NHRI:Item 3990099045/13662
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911899      Online Users : 1025
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13662


    Title: Covid‐19 vaccines in patients with maintenance hemodialysis
    Authors: Yen, CC;Lin, SY;Chen, SC;Chiu, YW;Chang, JM;Hwang, SJ
    Contributors: Institute of Population Health Sciences
    Abstract: The COVID‐19 pandemic has infected more than 180 million people and caused more than 3.95 million deaths worldwide. In addition to personal hygiene, augmented cleaning, social distancing, and isolation, vaccine development and immunization are essential for this highly contagious disease. Patients with maintenance hemodialysis (MHD) have a greater risk of COVID‐19 infection owing to their comorbidities, defective immunity, and repeated crowded in‐center dialysis settings. However, many patients hesitate to get vaccinated because of their misunderstandings. The Efficacy of COVID‐19 vaccination has been intensively discussed in the general population, whereas the data concerning the effectiveness of vaccination in MHD patients are relatively scanty. Nevertheless, those limited publications can provide some valuable information. Overall, lower and more delayed antibody responses following COVID‐19 vaccination were observed in patients with MHD than in healthy controls in the settings of different populations, vaccines and dosage, definitions of the immune response, and antibody detection timepoints. Younger age, previous COVID‐19 infection, and higher serum albumin level were positively associated with antibody formation, whereas older age and receiving immunosuppressive therapy were unfavorable factors. However, it remains uncertain between the elicited antibodies following vaccination and the genuine protection against COVID‐19 infection. Patients with MHD should make their COVID‐19 vaccination a priority in addition to other protective measures. More studies focusing on different vaccines, non‐humoral immune responses, and risk‐benefit analyses are warranted.
    Date: 2021-08-12
    Relation: Journal of personalized medicine. 2021 Aug 12;11(8):Article number 789.
    Link to: http://dx.doi.org/10.3390/jpm11080789
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2075-4426&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000689387600001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85113153456
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SCP85113153456.pdf269KbAdobe PDF198View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback